News : TrialNet

Diamyd Medical AB reports that the results of a study with the Company’s antigen-based diabetes therapy Diamyd®, conducted by the research consortium Type 1 Diabetes TrialNet did not show a statistically significant effect of the study drug.
The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd® yesterday, June 27, at...

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.
During the first quarter Diamyd Medical has reported several important events that have contributed positively to the Company’s development. The financial position has been...

Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America.
The TrialNet GAD study, conducted by an international network of leading pediatric and adult endocrinologists and immunologists, has...

Diamyd Medical announces today that Type 1 Diabetes TrialNet, a clinical network funded by the National Institutes of Health to prevent and treat newly diagnosed type 1 diabetes, has started recruiting patients for a clinical trial testing the Diamyd®-vaccine’s therapeutic benefit in individuals with recent-onset type 1 diabetes.
The study will, as previously announced, assess the vaccine’s ability to protect...

Diamyd Medical reports that the US Food and Drug Administration (FDA) has approved a study designed to preserve and possibly regenerate insulin production in patients with recent onset type 1 diabetes. The trial will test the diabetes vaccine Diamyd® in combination with drugs that are believed to stimulate new beta cell growth. The aim of the combination therapy is to try to restore lost insulin-producing capacity...